액티브 상처 치료 시장 : 시장 점유율 분석, 산업 동향 및 통계, 성장 예측(2025-2030년)

The Active Wound Care Market size is estimated at USD 3.02 billion in 2025, and is expected to reach USD 3.79 billion by 2030, at a CAGR of 4.64% during the forecast period (2025-2030).

The factors driving the market's growth include the high prevalence of acute and chronic wounds, the rising number of innovative product launches, and the increasing number of surgeries.

The rise in wound-related hospitalizations owing to an increase in surgical and pressure ulcer-prone wounds is expected to fuel the market growth. For instance, according to an article published by the Elsevier Journal in August 2022, critical care patients were at higher risk of developing pressure ulcers owing to their immobility, reliance on pressure relief devices, and regular position changes. Therefore, the high number of patients who are likely to develop pressure ulcers raises the demand for active wound care products for faster healing, propelling the market growth.

The prevalence of chronic diseases like diabetes, obesity, and cardiovascular conditions often leads to complications such as diabetic foot ulcers and arterial ulcers, which drive market growth. For instance, according to the 2022 data published by the International Diabetes Federation, about 643 million people are expected to suffer from diabetes globally by 2030. This number is projected to reach 784 million by 2045. The increase in the diabetic population raises the risk of developing diabetic foot ulcers, increasing the demand for ulcer dressings and skin substitutes that are effective in healing foot ulcers, thereby contributing to market growth.

The rising number of innovative product launches related to active wound care, specifically in the areas of biomaterials, skin substitutes, and growth factors, is expected to drive market growth during the forecast period. For instance, in May 2022, the Technical University of Munich (TUM) in Germany developed a new kind of film dressing using mucin biomolecules for the protection of wounds. This dressing is also incorporated with active pharmaceutical ingredients to accelerate wound healing, expel bacteria, inhibit inflammation, and finally decompose on the skin by itself.

In June 2022, Collagen Matrix Inc. received the US Food and Drug Administration approval for a new fibrillar collagen wound dressing. The Collagen Matrix Fibrillar Collagen Wound Dressing is an absorbent microfibrillar matrix used to treat wounds that moderately exude fluid and control mild bleeding. Therefore, the rising number of biomaterial-based wound care products by prominent players is projected to drive market growth during the forecast period.

Procedures like breast reconstruction, facial reconstruction, and body contouring surgeries are on the rise, often involving extensive tissue manipulation and reconstruction. For instance, according to the Cosmetic Surgery Statistics 2024 report, about 2 million surgical and non-surgical procedures are performed annually in the United States. In addition, an estimated 350 thousand breast augmentation procedures are expected to be performed in the United States in 2024. These procedures require advanced wound care products to promote healing and optimize cosmetic outcomes, driving the active wound care market's growth.

Hence, factors such as the increasing prevalence of acute and chronic wounds, the rising number of innovative product launches, and the increasing number of surgeries are projected to drive market growth during the forecast period.

Active Wound Care Market Trends

The Biomaterials Segment is Expected to Witness Significant Growth Over the Forecast Period

A biomaterial is a synthetic or natural substance that can either be inserted into the body as part of an implanted medical device or can be used to treat, augment, or replace tissue. The cell proliferative effects and biocompatibility of biomaterials are the major advantages; owing to this, their usage is expected to rise over the forecast period.

The factors driving the growth of the biomaterials segment include the advantages associated with biomaterials and the rising number of product developments by prominent players.

Biomaterials such as hydrogels, forms, and alginate dressings create and maintain a moist wound environment. This environment is conducive to healing as it promotes cell migration, facilitates oxygen and nutrient exchange, and supports the formation of granulation tissue.

Biomaterials such as collagen dressings are becoming more popular due to their effectiveness and ease of use. Companies are producing new products in biomaterial-based dressings, which is fueling the segment's growth. For instance, in June 2022, a new fibrillar collagen wound dressing was approved by the 510(k) regulatory agency for the US-based regenerative medicine company Collagen Matrix Inc. The Collagen Matrix Fibrillar Collagen Wound Dressing is an absorbent microfibrillar matrix used to manage minor bleeding and heal wounds that moderately to significantly discharge fluids.

In May 2022, Winner Medical Co. Ltd launched its latest advanced surgical wound care products, the Bordered Silicone Foam Dressing, Transparent Film Dressing, and Carboxymethylcellulose (CMC) Dressing, in Europe.

Several players are developing new advanced wound care dressings to manage chronic wounds. For instance, in June 2022, Smith & Nephew announced its newest R&D and manufacturing site in the United Kingdom to improve wound management. The investment for this wound management facility was USD 100 million. With such a massive investment in wound care, the biomaterials segment is expected to witness healthy growth during the forecast period.

Therefore, owing to the various advantages of biomaterials in managing acute and chronic wounds and the launch of new products, the segment is expected to witness significant growth during the forecast period.

North America is Expected to Register Significant Growth in the Market Over the Forecast Period

North America is expected to hold the largest share in the active wound care market over the forecast period owing to factors such as increasing cases of chronic and acute wounds, advanced treatment options, and the rising number of surgeries in the region.

The increasing number of chronic and acute wounds in the United States is one of the major drivers for the market. As per the 2022 data published by the International Diabetes Federation, about 35 million people in the United States are expected to have diabetes by 2030; this number is projected to reach 36 million by 2045. Diabetic foot ulcers are one of the most common complications for diabetic patients. Thus, such a high population of diabetic patients in the United States is expected to propel the demand for active wound care products.

As per the Mission Regional Medical Center's 2022 update, it was estimated that 6.7 million people had chronic wounds in the country. This number is expected to grow by more than 2.0% in the next decade. Active wound care aims to prevent amputations and heal patients more quickly and affordably. Hence, considering its advantages, the adoption rate of active wound care is expected to rise in the United States during the forecast period.

The rising number of product launches in the country is anticipated to increase the availability of active wound care products and their adoption among patients, boosting market growth over the forecast period. In May 2023, Bioventus Inc. signed an agreement to sell its wound business, including the skin substitutes TheraSkin and TheraGenesis, to LifeNet Health. Bioventus and LifeNet Health also signed a sales agent agreement to provide LifeNet Health exclusive rights to sell SonicOne Ultrasonic wound debridement products in the United States and Canada.

In September 2022, Arch Therapeutics Inc., a marketer and developer of novel self-assembling wound care and biosurgical products, announced the first shipments of the AC5 Advanced Wound System (AC5) under the company's new reimbursement support program. This development represented a significant milestone in the company's overall commercialization efforts, supporting the accelerated growth and utilization of AC5 in doctor's offices and wound care clinics.

Therefore, the rising number of acute and chronic wounds, collaborations, and product launches in the region is expected to drive market growth over the forecast period.

Active Wound Care Industry Overview

The active wound care market is moderately fragmented due to the presence of a few companies operating globally. The companies are adopting key strategic activities such as new product launches, collaborations, and partnerships to retain their market position. Some of the key players in the market are Smith & Nephew PLC, MiMedx Group Inc., Tissue Regenix Group, Organogenesis Inc., and Integra LifeSciences.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Prevalence of Acute and Chronic Wounds
  • 4.2.2 Rising Number of Innovative Product Launches
  • 4.2.3 Increase In Number of Surgeries
• 4.3 Market Restraints
  • 4.3.1 High Cost and Lack of Reimbursements
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 By Product
  • 5.1.1 Biomaterials
  • 5.1.2 Skin Substitutes
    • 5.1.2.1 Biological Skin Substitutes
    • 5.1.2.2 Synthetic and Biosynthetic Skin Substitutes
  • 5.1.3 Growth Factors
• 5.2 By End User
  • 5.2.1 Hospitals
  • 5.2.2 Clinics
  • 5.2.3 Home Healthcare
• 5.3 By Application
  • 5.3.1 Chronic Wounds
  • 5.3.2 Acute Wounds
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Smith and Nephew PLC
  • 6.1.2 MiMedx Group Inc.
  • 6.1.3 Tissue Regenix Group
  • 6.1.4 Organogenesis Inc.
  • 6.1.5 Molnlycke Health Care AB
  • 6.1.6 Integra LifeSciences
  • 6.1.7 3M Company
  • 6.1.8 Human BioSciences
  • 6.1.9 Fibroheal Woundcare Pvt. Ltd
  • 6.1.10 Stryker Corporation (Wright Medical Group NV)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS